Smartlab Europe

Drug Research

Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease

Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage...

Marinus Pharma Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

Marinus Pharmaceuticals Inc , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders announced that the U.S. FDA has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment...

Clinical research data sharing promises new cures and treatments

Clinical research generates extensive amounts of data, yet most of it is siloed or generally unavailable to a larger pool of willing potential researchers. If this data were liberated to the masses, we would venture into a world of endless...

Glenmark Pharma gets USFDA approval for Tretinoin Capsules

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Tretinoin. Capsules, 10 mg, the generic version of Vesanoid Capsules, 10 mg, of Hoffmann La...

IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery

IBM Watson Health and Pfizer Inc announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer....

Global market will reach $26 billion by 2020, says GBI Research

The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020, according to business intelligence firm GBI Research. The company’s latest report states that the emergence of...

Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, Amphetamine, for the Treatment of ADHD

Neos Therapeutics a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit hyperactivity disorder (ADHD), announced that it has submitted a NDA to the U.S. FDA for its Amphetamine...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »